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ABSTRACT
Objectives: This study aimed to identify patients with high-probability of ocular involvement of
Behc¸et’s disease (BD).
Methods: The Japanese Ministry of Health, Labour and Welfare provided dataset of ongoing nation-
wide BD registration project. A patient who had confirmed BD and who was suspected to have BD
was registered. We mainly analyzed newly registered patients who had the data for all demographic
and diagnostic parameters regardless of fulfilment of any diagnostic criteria.
Results: Among 3213 patients with confirmed or possible BD, 1382 (43.0%) were men and 1831
(57.0%) were women with a median age of 38 years (interquartile range (IQR) 30–49 years). The
median duration between onset and registration was 0 year (IQR 0–3). A binomial multivariable logistic
regression analysis revealed that being female (odds ratio (OR) 0.63, 95% confidence interval (CI)
0.53–0.75, p< .001), duration since onset (OR 1.33 per 10 years, 95% CI 1.18–1.51, p< .001), genital
ulceration (OR 0.28, 95% CI 0.23–0.34, p< .001), and gastrointestinal symptoms (OR 0.36, 95% CI
0.30–0.44, p< .001) were related to the ocular lesion. Analyses based on data of 2800 patients who sat-
isfied International criteria of BD, age-, sex-, duration-based subgroup analyses, analyses targeting irido-
cyclitis and retino-uveitis, and analysis including patients with missing data confirmed that the four
factors were associated with the probability of eye involvement.
Conclusion: The ocular involvement did not accompany with genital ulcer or gastrointestinal symp-
toms at the early stage of BD.
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Introduction
Behc¸et’s disease (BD) is a chronic inflammatory syndrome
with features of multi-organ involvement and presents with
mucocutaneous and ocular symptoms [1,2]. The etiology still
remains unclear, although both genetic and environmental
factors are implicated in the immunological abnormalities
leading to the development of BD [3–6]. Unique geograph-
ical distribution of the patients along the ancient Silk Road
and high prevalence of HLA-B51 have suggested significant
implication of the genetic factors. Recent genome wide asso-
ciation study (GWAS) and subsequent detailed genetic anal-
yses have identified a number of disease susceptibility genes
of BD, in addition to HLA-B51 [3–5,7,8]. Most of them
encode immunological functional molecules, which are
involved in both the acquired and innate immune systems
including the pathogen recognition sensors [9]. Thus, the
genetic studies have provided evidence of the involvement
of environmental factors in the development of BD.
BD has a broad spectrum of clinical manifestations and
varied severity from patient to patient [1,2]. Demographic
backgrounds are implicated in the differences in clinical
manifestations, as a number of studies have shown that
male patients with young age of onset have more frequent
ocular and vascular involvement [10–12]. Although HLA-
B51 is the most common predisposing factor in BD, two
meta-analyses have shown that HLA-B51 affects the clinical
presentation of the disease [13,14]. BD patients with HLA-
B51 more commonly present with ocular lesion, skin
symptoms, and genital ulcers, but have a lower incidence
of intestinal involvement than HLA-B51 negative patients
[13,14]. Similarly, several studies have also shown the
association of genetic factors such as HLA typing and
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polymorphisms of cytokines with particular manifestations
in BD [15–17].
A couple of studies have revealed some phenotypical
clustering among the patients with BD [18,19]. Hatemi et al.
found a subtype presenting with papulopustular eruptions,
arthritis and enthesopathy without vascular lesions [18]. The
subsequent study showed familial clustering of the subtype,
suggesting the role of genetic factors [20].
This study aimed to identify patients with high probabil-
ity of ocular involvement. To this end, we investigated the
association of eye lesions with demographic findings and
extraocular manifestations particularly in the early phase of
BD, using a nationwide Japanese registration database.
Methods
Overview
The Japanese Ministry of Health, Labour and Welfare has
been carrying out this ongoing nationwide registration pro-
ject since 2001 [21]. When a physician suspected that a
patient had BD, the physician needed to register the
patient’s data by filling up a questionnaire. For this purpose,
the physician can suspect BD, regardless of rigid BD criteria,
based on one or more of typical symptoms: major symptoms
namely aphthous oral ulceration, skin lesions, ocular lesion,
and genital ulceration; minor symptoms namely arthritis,
epididymitis, gastrointestinal symptoms, vascular lesions,
and neurological manifestations. This registration was
required for a BD patient to obtain the free medical facilities
in Japan. Thus, we believed that a large part of the patients
who were confirmed to have BD or suspected to have BD
were registered in this database [21].
This registration had two independent databases. One
database was for new cases and the other was for previously
registered cases. We used only the former database to avoid
duplicate use of data from the same patients [21].
The ministry provided the dataset to us after un-linkable
anonymization. For the current analysis, we utilized the
database from 2003 because the data format was changed in
2003. Our analysis followed the Ethical Guidelines for
Medical and Health Research Involving Human Subjects,
which was published in 2015 by the Ministry of Health,
Labour and Welfare, Japan [22]. Informed consent of
patients and institutional review board approval were not
required as this study dealt only un-linkably anonymized
data set [22].
Diagnostic criteria
Among the cases in the database of new patients, we mainly
analyzed the data of patients whose data were not missing
for any diagnostic items. In addition, we used a cohort of
patients who satisfied International Criteria of BD
(ICBD) [23].
The data of individual BD cases were usually registered
by a rheumatologist supported by medical doctors in other
specialties. However, a general physician, gastroenterologist,
dermatologist, ophthalmologist, or a neurologist could also
register the patient data.
Oral ulceration was diagnosed based on recurrent well-
defined shallow aphthous oral ulcers that may appear on
oral mucosa including labial mucosa, buccal mucosa, tongue,
and gingiva. Skin lesions were diagnosed based on erythema
nodosum typically appearing in the lower limbs; hypocuta-
neous thrombophlebitis; folliculitis and acne typically
appearing on the face, neck, and back. Ocular lesions were
diagnosed based on bilateral uveitis with episodic attack of
conjunctival congestion, ophthalmalgia, decreased visual
acuity, and visual field deficit. Genital ulceration was diag-
nosed based on well-defined painful aphthous ulcer typically
appearing on the scrotum and penis of a male and the labia
major and labia minor of a female. More detailed descrip-
tion of each manifestation is available elsewhere [21].
Statistics
Patients who were re-registered erroneously and patients
whose data were missing for at least one domain of our con-
cern were deleted prior to our main analysis. A binomial
multivariable logistic regression analysis without variable
selection was used to assess the association between the ocu-
lar lesion and the other parameters. In this process, we had
identified that the genital ulceration and gastrointestinal
symptoms were preventive factors for ocular lesions. Thus,
following analyses focused on these manifestations.
Sensitivity analyses using data of subgroups, stratified by
sex, age, onset-registration duration were performed. We
also carried out sensitivity analyses concerning iridocyclitis
and retino-uveitis instead of general ocular lesions.
Another additional sensitivity binomial multivariable
logistic regression analysis was done in a larger cohort
including patients with missing data. Patient who had data
of major factors namely sex, duration since once, genital
ulceration, and gastrointestinal symptoms were analyzed.
This sensitivity analysis allowed missing other items such as
pathergy test to maximize the cohort size. These four
parameters were chosen because they showed highly signifi-
cant relationship with the ocular lesion in the previous logis-
tic regression analysis.
We used a statistical software, BellCurve for Excel (Social
Survey Research Information Co., Ltd., Tokyo, Japan).
Results
Flowchart for patient screening
The database for newly diagnosed cases included 9045 indi-
vidual cases. After eliminating 379 duplicate registrations
and 5453 invalid cases, 3213 cases who had data for all
items were eligible for our main analysis (Figure 1). The
most common cause of invalid data was an unknown status
of pathergy test, which is a reference finding but not essen-
tial for the diagnosis according to the Japan criteria. Among
3213 eligible cases, 2800 (87.1%) cases fulfilled the ICBD
(Table 1).
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Background characteristics of 3213 patients in the
main analysis
Table 1 summarizes the patient profiles. Among 3213 con-
firmed or possible BD patients who were listed in the regis-
try without missing data, 1382 (43.0%) were men and 1831
(57.0%) were women with a median age of 38 years (inter-
quartile range (IQR) 30–49 years) (Table 1). The median age
of onset was 36 years (IQR 27–45). The median duration
between onset and registration was 1 year (IQR 0–3). While
1593 (49.6%) cases were registered within a year since onset,
383 (11.9%) cases presented with any of BD symptoms
more than 10 years before the registration (Table 1). Among
3213 cases, 2713 (84.4%), 2399 (74.7%), and 2800 (87.1%)
satisfied Japanese criteria, the International Study Group
(ISG) criteria, and ICBD, respectively.
Binomial multivariable logistic regression analysis
Based on the logistic regression analysis using the data of
the 3213 cases, being female (odds ratio (OR) 0.63, 95%
confidence interval (CI) 0.53–0.75, p< .001), duration since
onset (OR 1.33 per 10 years, 95% CI 1.18–1.51, p< .001),
genital ulceration (OR 0.28, 95% CI 0.23–0.34, p< .001),
and gastrointestinal symptoms (OR 0.36, 95% CI 0.30–0.44,
p< .001) were positively or negatively related to the ocular
lesion (Table 2).
The associations between these four parameters and ocu-
lar lesion were replicated in a cohort of 2800 patients who
satisfied ICBD (Table 2).
Analyses with genital ulceration and gastrointestinal
symptoms in subgroups
Subgroup analyses were carried out to validate the associ-
ation between genital ulcer, gastrointestinal symptoms, and
eye involvement. In both man (OR 0.36, 95% CI 0.29–0.46,
p< .001) and woman (OR 0.29, 95% CI 0.23–0.37, p< .001)
subgroups, patients with genital ulceration was related to the
lower possibility of ocular lesion (Table 3). Among patients
with symptoms that last more than 10 years, genital ulcer-
ation was not related to eye lesion (OR 0.80, 95% CI
0.51–1.23, p< .001).
Table 1. Background patient characteristics.
All cases without
missing data
International criteria
of Behc¸et's disease
N 3213 2800
Age year, median (IQR) 38 (IQR 30–49) 38 (IQR 30–47)
Men 1382 (43.0%) 1141 (40.8%)
Women 1831 (57.0%) 1659 (59.3%)
Oral ulceration 3044 (94.7%) 2765 (98.8%)
Onset registration duration (years) 1 (IQR 0–3) 0 (IQR 0–3)
0–0.99 year 1593 (49.6%) 1410 (50.4%)
1–9.99 years 1237 (38.5%) 1065 (38.0%)
10 years 383 (11.9%) 324 (11.6%)
Skin lesion 2673 (83.2%) 2450 (87.5%)
Ocular lesion 891 (27.7%) 847 (30.3%)
Genital ulceration 2101 (65.4%) 2088 (74.6%)
Positive pathergy test 1016 (31.6%) 1000 (35.7%)
Arthritis 1620 (50.4%) 1461 (52.2%)
Epididymitis (male only) 126/1382 (9.1%) 111/1142 (9.7%)
Gastrointestinal symptom 998 (31.1%) 790 (28.2%)
Vascular lesion 368 (11.5%) 343 (12.3%)
Neurological manifestation 692 (21.5%) 633 (22.6%)
Iridocyclitis 637 (19.8%) 607 (21.7%)
Retino-uveitis 596 (18.5%) 562 (20.1%)
International criteria of Behc¸et's
disease
2800 (87.1%) 2800 (100.0%)
International Study Group criteria 2399 (74.7%) 2399(85.7%)
Japanese criteria 2713 (84.4%) 2611 (93.3%)
Figure 1. Flowchart of patients screening.
Table 2. Binomial multivariable regression analysis to predict ocular lesion.
Odds ratio (95% CI) p
All cases without missing data (N¼ 3213)
Age (10 years) 1.01 (0.95–1.07) .838
Female 0.63 (0.53–0.75) <.001
Onset-registration duration (10 years) 1.33 (1.18–1.51) <.001
Oral ulcer 1.04 (0.72–1.48) .848
Skin lesion 0.83 (0.66–1.06) .130
Genital ulceration 0.28 (0.23–0.34) <.001
Positive pathergy test 1.19 (0.99–1.43) .066
Arthritis 0.93 (0.79–1.11) .443
Gastrointestinal symptoms 0.36 (0.30–0.44) <.001
Vascular lesion 0.73 (0.56–0.95) .022
Neurological manifestation 0.87 (0.70–1.06) .171
International criteria of Behc¸et's disease (N¼ 2800)
Age (10 years) 1.05 (0.98–1.13) .171
Female 0.60 (0.49–0.72) <.001
Onset-registration duration (10 years) 1.51 (1.31–1.74) <.001
Oral ulcer 0.12 (0.05–0.29) <.001
Skin lesion 0.46 (0.35–0.61) <.001
Genital ulceration 0.12 (0.10–0.15) <.001
Positive pathergy test 0.84 (0.68–1.02) .079
Arthritis 0.86 (0.71–1.04) .127
Gastrointestinal symptoms 0.46 (0.37–0.58) <.001
Vascular lesion 0.48 (0.36–0.66) <.001
Neurological manifestation 0.69 (0.54–0.87) .002
Epididymitis were not used as independent variables.
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Gastrointestinal symptoms were inversely suspected with
the eye involvement in any subgroups such as sex-, age-,
duration-specific patient subgroups (Table 3).
Relationship between genital ulceration, gastrointestinal
symptom, iridocyclitis, and retino-uveitis
Regarding the localization of ocular lesions, genital ulcer-
ation decreased the probability of both iridocyclitis (OR
0.30, 95% CI 0.25–0.36, p< .001) and retino-uveitis (OR
0.29, 95% CI 0.24–0.35, p< .001) (Table 3). Having gastro-
intestinal symptoms decreased the possibility of iridocyclitis
(OR 0.38, 95% CI 0.30–0.47, p< .001) and retino-uveitis
(OR 0.44, 95% CI 0.35–0.54, p< .001) in the analysis of
3213 cases (Table 3).
Binomial multivariable logistic regression analysis to
predict ocular lesion by four major variables in a
larger cohort
As a sensitivity analysis, we carried out a binomial multi-
variable logistic regression analysis using data of patient
who had data of four major factors namely sex, duration
since once, genital ulceration, and gastrointestinal symp-
toms. For this analysis, missing other items such as pathergy
test was allowed to maximize the cohort size. This analysis
included 6989 cases, of which 5865 (83.9%), 5048 (72.2%),
and 5973 (85.5%) satisfied Japanese criteria, ISG criteria,
and ICBD. Female sex (OR 0.62, 95% CI 0.55–0.69,
p< .001), onset registration duration (OR 1.36 per 10 year,
95% CI 1.28–1.46, p< .001), genital ulceration (OR 0.33,
95% CI 0.30–0.37, p< .001), and gastrointestinal symptoms
(OR 0.35, 95% CI 0.31–0.4, p< .001) were associated to ocu-
lar manifestation probability, which validated the results
from our main analysis (Table 4).
A subgroup analysis focusing on 5865 patients who satis-
fied Japanese criteria replicated the results (Table 4).
Among 1124 cases without fulfilling Japanese criteria, no
patient had both eye involvement and genital ulceration.
Therefore, these symptoms were assumed to exist exclusively
in this group. A logistic regression excluding genital ulcer-
ation from the explanatory variables also revealed that the
remaining three parameters were related to ocular manifest-
ation possibility (Table 4).
Discussion
This study aimed to identify the early phase of clinical fea-
tures in BD patients presenting with ocular involvement
using the nationwide Japanese registration database, which
was the largest data source ever reported. We found a nega-
tive association of ocular involvement with genital ulceration
or gastrointestinal symptoms. The negative association was
also confirmed by sensitivity analyses focusing on sub-
groups, iridocyclitis, and retino-uveitis. The present study
also showed that the patients having ocular involvement
were more likely to be associated with male gender and lon-
ger duration since onset. As clinical manifestations of BD
are diverse and heterogeneous, it is very helpful to clarify
the positive or negative association of ocular involvement
with extraocular manifestations and patient demography.
Previous studies with more than 100 patients from vari-
ous countries have shown that the prevalence of eye involve-
ment in BD patients ranged from 28% to 76% and that the
male predominance was one of the most consistent findings,
irrespective of the geographical distribution and ethnicity
[10–12,24]. Gender also has a significant impact on the
severity of eye involvement, as shown by Tursen et al. from
Turkey [11]. In a retrospective study analyzing 164 BD
patients who received long-term infliximab therapy for
Table 3. Contingency tables for genital ulcer, gastrointestinal symptom, and ocular lesions.
N¼ 3213 Genital ulceration Gastrointestinal symptom
Subgroup (þ) (–) Odds ratio (95% CI), p (þ) (–) Odds ratio (95% CI), p
All (N¼ 3213) Ocular lesion (þ) 395 496 0.29 (0.25–0.34) 177 714 0.45 (0.38–0.55)
Ocular lesion (–) 1706 616 <.001 821 1501 <.001
Male (N¼ 1382) Ocular lesion (þ) 174 327 0.36 (0.29–0.46) 83 418 0.30 (0.23–0.39)
Ocular lesion (–) 524 357 <.001 354 527 <.001
Female (N¼ 1831) Ocular lesion (þ) 221 169 0.29 (0.23–0.37) 94 296 0.66 (0.51–0.86)
Ocular lesion (–) 1182 259 <.001 467 974 .002
Age 37.99 years (N¼ 1508) Ocular lesion (þ) 183 199 0.24 (0.19–0.17) 66 316 0.40 (0.30–0.54)
Ocular lesion (–) 893 233 <.001 385 741 <.001
Age 38 years (N¼ 1705) Ocular lesion (þ) 212 297 0.34 (0.27–0.42) 111 398 0.49 (0.38–0.62)
Ocular lesion (–) 813 383 <.001 436 760 <.001
Onset, 0.99 years (N¼ 1593) Ocular lesion (þ) 175 223 0.25 (0.20–0.32) 74 324 0.42 (0.32–0.55)
Ocular lesion (–) 903 292 <.001 422 773 <.001
Onset, 1–9.99 years (N¼ 1237) Ocular lesion (þ) 132 222 0.23 (0.18–0.30) 69 285 0.44 (0.32–0.59)
Ocular lesion (–) 636 247 <.001 315 568 <.001
Onset, 10 years (N¼ 383) Ocular lesion (þ) 88 51 0.80 (0.51–1.23) 34 105 0.62 (0.39–0.99)
Ocular lesion (–) 167 77 .313 84 160 .042
All (N¼ 3213) Iridocyclitis (þ) 269 368 0.30 (0.25–0.36) 106 531 0.38 (0.30–0.47)
Iridocyclitis (–) 1832 744 <.001 892 1684 <.001
All (N¼ 3213) Retino-uveitis (þ) 246 350 0.29 (0.24–0.35) 109 487 0.44 (0.35–0.54)
Retino-uveitis (–) 1855 762 <.001 889 1728 <.001
Onset: duration from the onset to registration.
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refractory retino-uveitis, 133 patients (81%) were males, also
indicating that serious eye involvement is more frequent in
males than females [25].
While the prevalence of eye involvement had been
reported as 67% and 69% in previous nationwide surveys in
Japan in 1972 and 1991, respectively [1]; it is reported as
27.7% of 3213 patients in the main analysis and 30.3% of
the patients who fulfilled the ICBD, in the present study.
The discrepancy was partly caused by a recent trend that the
ocular involvement has been becoming less frequent in
Japan [26]. In addition, the present cross-sectional study
might miss some patients who develop ocular involvement
later, because more than half of the patients were registered
within one year from the onset. Clinical phenotypes may be
premature in these patients, and evolved and accumulated
even after making the diagnosis. Actually, a stratified sub-
group analysis in the present study did not show consider-
able negative association between ocular involvement and
genital ulceration or gastrointestinal symptoms in patients
with 10 years or more of disease duration at the registry
(Table 3). Thus, it is likely that the exclusive relationship
between ocular involvement and genital ulceration or gastro-
intestinal symptoms reflects distinct subtypes among BD
patients rather than effects of premature presentations.
It is hard to identify the factors causing the exclusive pre-
sentations between ocular involvement and genital ulceration
or gastrointestinal symptoms observed in this study. One of
the possible factors is sex hormone, which has been
described to affect the ocular lesions genital ulceration, and
gastrointestinal symptoms [27–31]. Of note, however, our
present study demonstrated that male gender, absence of
genital ulceration, and absence of gastrointestinal symptoms
independently contributed to a high probability of the ocular
involvement.
Genetic factor is another possibility. Interestingly, the
papulopustular lesion/arthritis cluster of Behc¸et's syndrome
is also shown to cluster in families, suggesting the possible
role of genetic factors in the specific subtype [20].
Therefore, it is interesting to determine the contribution of
individual disease susceptibility genes to the development of
a particular symptom or a particular phenotype of BD
patients. In multifactorial diseases such as bronchial asthma,
genetic heterogeneity is becoming clear among distinct
asthma phenotypes, identified by a clustering approach [32].
Such approaches may be applicable for BD.
We should comment on a few limitations of this study.
First, this was a cross-sectional study in which majority of
the patients were in the early phase of disease, because they
were registered to receive financial support for medical
costs. As previously discussed, clinical phenotypes may be
premature in some patients. Therefore, we believe our study
presented data that were largely derived from treatment-
naïve patients [26,33], though some patients may be affected
by immunosupressants. Second, having one item in the diag-
nostic criteria may decrease the possibility of having another
item for a patient who has recently fulfilled the minimum
score of the criteria. This bias is most strongly observed in
ISG criteria, because two among four major symptoms are
mandatory. We used ICBD, which allows great variety of
combination of diagnostic symptoms, not Japanese criteria
nor ISG criteria, in this study to minimize this bias.
Furthermore, a large part of our analysis used a cohort
regardless of fulfilment of BD diagnostic criteria to avoid
this bias.
In conclusion, according to a large nationwide BD regis-
tration using data of patients who were diagnosed to have
BD or were suspected to have BD, the ocular involvement
did not accompany with genital ulcer or gastrointestinal
symptoms at the early stage of BD.
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